NasdaqGS:PGENBiotechs
Precigen (PGEN) Is Up 24.4% After FDA Approval and US Launch of Papzimeos – Has the Bull Case Changed?
Earlier this week, Precigen announced it received full FDA approval and launched Papzimeos in the US as the first and only available therapy for adults with recurrent respiratory papillomatosis, rapidly engaging over 90% of target institutions and registering more than 100 patients to date.
This significant regulatory achievement marks Precigen’s shift from a development-stage to a commercial-stage biopharmaceutical company, opening new revenue streams but also highlighting its financial...